TNFRSF10A and neoplasm: Epigenetic dysregulation of TRAIL antagonistic receptors, TRAIL-R3 and TRAIL-R4, or of TRAIL agonistic receptors TRAIL-R1 and TRAIL-R2, has been documented to varying extents [155-157], leading to the loss of expression of the receptors in tumor cells and giving rise to resistance to TRAIL-induced cell death [158].